8 ud af 8 tidsskrifter valgt, søgeord (covid) valgt, emner højest 180 dage gamle, sorteret efter nyeste først.
165 emner vises.
51
Respiratory Virus Surge: Diagnosing COVID-19 vs RSV, Flu
Medscape Infectious Diseases, 1.02.2024
Tilføjet 1.02.2024
Amid the current winter wave surge of respiratory virus cases, how challenging is it for physician\'s to distinguish between, diagnose, and treat COVID-19 vs RSV and influenza? Medscape Medical News
Læs mere
52
Vaccination coverage in the EU/EEA during Autumn 2023 campaigns
ECDC
ECDC COVID-19 updates, 26.01.2024
Tilføjet 26.01.2024
Nearly 20 million people aged 60 years and above received COVID-19 vaccines during the autumn / winter campaign in the EU/EEA
Læs mere
53
Interim COVID-19 vaccination coverage in the EU/EEA during the 2023–24 season campaigns
ECDC
ECDC COVID-19 updates, 26.01.2024
Tilføjet 26.01.2024
This report presents an interim description of COVID-19 vaccine coverage in the European Union/European Economic Area (EU/EEA) between 1 September 2023 and January 2024.
Læs mere
54
Age-dependent influenza infection patterns and subtype circulation in Denmark, in seasons 2015/16 to 2021/22
Hanne-Dorthe Emborg, Amanda Bolt Botnen, Jens Nielsen, Lasse S. Vestergaard, Frederikke Kristensen Lomholt, Charlotte Munkstrup, Karina Lauenborg Møller, Charlotte Kjelsø, Steen Hulthin Rasmussen and Ramona Trebbien
Eurosurveillance latest updates, 26.01.2024
Tilføjet 26.01.2024
BackgroundInfluenza was almost absent for 2 years following the implementation of strict public health measures to prevent the spread of SARS-CoV-2. The consequence of this on infections in different age groups is not yet known. AimTo describe the age groups infected with the influenza virus in 2021/22, the first post-pandemic influenza season in Denmark, compared with the previous six seasons, and subtypes circulating therein. MethodsInfection and hospitalisation incidences per season and age group were estimated from data in Danish registries. Influenza virus subtypes and lineages were available from samples sent to the National Influenza Centre at Statens Serum Institut. ResultsTest incidence followed a similar pattern in all seasons, being highest in 0–1-year-olds and individuals over 75 years, and lowest in 7–14-year-olds and young people 15 years to late twenties. When the influenza A virus subtypes A(H3N2) and A(H1N1)pdm09 co-circulated in seasons 2015/16 and 2017/18 to 2019/20, the proportion of A(H1N1)pdm09 was higher in 0–1-year-olds and lower in the over 85-year-olds compared with the overall proportion of A(H1N1)pdm09 in these seasons. The proportion of A(H3N2) was higher in the over 85 years age group compared with the overall proportion of A(H3N2). The 2016/17 and 2021/22 seasons were dominated by A(H3N2) but differed in age-specific trends, with the over 85 years age group initiating the 2016/17 season, while the 2021/22 season was initiated by the 15–25-year-olds, followed by 7–14-year-olds. ConclusionThe 2021/22 influenza season had a different age distribution compared with pre-COVID-19 pandemic seasons.
Læs mere
55
Authors’ response: Added value of backward contact tracing for COVID-19
Timo Louis Boelsums, Maaike Buskermolen and on behalf of all co-authors of the original article
Eurosurveillance latest updates, 26.01.2024
Tilføjet 26.01.2024
56
Underuse of Antiviral Drugs to Prevent Progression to Severe COVID-19 - Veterans Health Administration, March-September 2022
Morbidity and Mortality Weekly Report (MMWR), 26.01.2024
Tilføjet 26.01.2024
This report describes a review of immunosuppressed patients with nonsevere COVID-19 who were not treated with an antiviral drug.
Læs mere
57
Five Bold Predictions for Long COVID in 2024
Medscape Infectious Diseases, 25.01.2024
Tilføjet 25.01.2024
If even one of these comes true, long COVID sufferers could enjoy some much-needed relief. Medscape Medical News
Læs mere
58
Picture of COVID-19 in Europe Is Complex
Medscape Infectious Diseases, 24.01.2024
Tilføjet 24.01.2024
Infection rates are declining overall, but continuing vigilance is crucial, said WHO. Medscape Medical News
Læs mere
59
CDC Says JN.1 Variant Accounts for About 86% Of COVID Cases in US
Medscape Infectious Diseases, 24.01.2024
Tilføjet 24.01.2024
The U.S. Centers for Disease Control and Prevention (CDC) on Monday estimated COVID subvariant JN.1 to account for about 85.7% of cases in the United States, as of Jan.... Reuters Health Information
Læs mere
60
Forskere har fundet ud af, hvem der især blev ramt af senfølger efter covid-19
Statens Serum Institut, 23.01.2024
Tilføjet 23.01.2024
Personer over 35 år, kvinder, overvægtige og mennesker med lidelser som depression og astma var særligt udsatte for senfølger efter covid-19 infektion tidligt i pandemien, konkluderer ny undersøgelse.
Læs mere
61
Why Are Women More Likely to Get Long COVID?
Medscape Infectious Diseases, 20.01.2024
Tilføjet 20.01.2024
Emerging research showing links to female reproductive health may offer clues to why women experience long COVID at nearly twice the rate of men. Medscape Medical News
Læs mere
62
Time trends and modifiable factors of COVID-19 contact tracing coverage, Geneva, Switzerland, June 2020 to February 2022
Denis Mongin, Nils Bürgisser, the Covid-SMC Study Group and Delphine Sophie Courvoisier
Eurosurveillance latest updates, 19.01.2024
Tilføjet 19.01.2024
BackgroundContact tracing was one of the central non-pharmaceutical interventions implemented worldwide to control the spread of SARS-CoV-2, but its effectiveness depends on its ability to detect contacts. AimEvaluate the proportion of secondary infections captured by the contact tracing system in Geneva. MethodsWe analysed 166,892 concomitant infections occurring at the same given address from June 2020 until February 2022 using an extensive operational database of SARS-CoV-2 tests in Geneva. We used permutation to compare the total number of secondary infections occurring at the same address with that reported through manual contact tracing. ResultsContact tracing captured on average 41% of secondary infections, varying from 23% during epidemic peaks to 60% during low epidemic activity. People living in wealthy neighbourhoods were less likely to report contacts (odds ratio (OR): 1.6). People living in apartment buildings were also less likely to report contacts than those living in a house (OR: 1.1–3.1) depending on the SARS-CoV-2 variant, the building size and the presence of shops. This under-reporting of contacts in apartment buildings decreased during periods of mandatory wearing of face masks and restrictions on private gatherings. ConclusionContact tracing alone did not detect sufficient secondary infections to reduce the spread of SARS-CoV-2. Campaigns targeting specific populations, such as those in wealthy areas or apartment buildings, could enhance coverage. Additionally, measures like wearing face masks, improving ventilation and implementing restrictions on gatherings should also be considered to reduce infections resulting from interactions that may not be perceived as high risk.
Læs mere
63
Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023
Liliana Antunes, Clara Mazagatos, Iván Martínez-Baz, Verónica Gomez, Maria-Louise Borg, Goranka Petrović, Róisín Duffy, François E Dufrasne, Ralf Dürrwald, Mihaela Lazar, Ligita Jancoriene, Beatrix Oroszi, Petr Husa, Jennifer Howard, Aryse Melo, Francisco Pozo, Gloria Pérez-Gimeno, Jesús Castilla, Ausenda Machado, Aušra Džiugytė, Svjetlana Karabuva, Margaret Fitzgerald, Sébastien Fierens, Kristin Tolksdorf, Silvia-Odette Popovici, Auksė Mickienė, Gergő Túri, Lenka Součková, Nathalie Nicolay, Angela MC Rose and on behalf of the European Hospital Vaccine Effectiveness Group
Eurosurveillance latest updates, 19.01.2024
Tilføjet 19.01.2024
We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14–89 days post-vaccination, 15% (95% CI: −12 to 35) at 90–179 days, and lower to no effect thereafter.
Læs mere
64
Study Estimates Post-COVID Risk for Alopecia Areata
Medscape Infectious Diseases, 15.01.2024
Tilføjet 15.01.2024
The incidence of alopecia areata in patients with COVID-19 was significantly higher than that in the uninfected controls, in a large Korean cohort study. MDedge News
Læs mere
65
RespiCast: the new European Respiratory Diseases Forecasting Hub
ECDC
ECDC COVID-19 updates, 15.01.2024
Tilføjet 15.01.2024
The European Respiratory Diseases Forecasting Hub (RespiCast) is open for weekly submission of several respiratory disease indicators such as influenza-like-illness, acute respiratory infection and COVID-19.
Læs mere
66
Impact of sex and gender on post-COVID-19 syndrome, Switzerland, 2020
Caroline E Gebhard, Claudia Sütsch, Pimrapat Gebert, Bianca Gysi, Susan Bengs, Atanas Todorov, Manja Deforth, Philipp K Buehler, Alexander Meisel, Reto A Schuepbach, Annelies S Zinkernagel, Silvio D Brugger, Claudio Acevedo, Dimitri Patriki, Benedikt Wiggli, Jürg H Beer, Andrée Friedl, Raphael Twerenbold, Gabriela M Kuster, Hans Pargger, Sarah Tschudin-Sutter, Joerg C Schefold, Thibaud Spinetti, Chiara Henze, Mina Pasqualini, Dominik F Sager, Lilian Mayrhofer, Mirjam Grieder, Janna Tontsch, Fabian C Franzeck, Pedro D Wendel Garcia, Daniel A Hofmaenner, Thomas Scheier, Jan Bartussek, Ahmed Haider, Muriel Grämer, Nidaa Mikail, Alexia Rossi, Núria Zellweger, Petra Opić, Angela Portmann, Roland von Känel, Aju P Pazhenkottil, Michael Messerli, Ronny R Buechel, Philipp A Kaufmann, Valerie Treyer, Martin Siegemund, Ulrike Held, Vera Regitz-Zagrosek and Catherine Gebhard
Eurosurveillance latest updates, 12.01.2024
Tilføjet 12.01.2024
BackgroundWomen are overrepresented among individuals with post-acute sequelae of SARS-CoV-2 infection (PASC). Biological (sex) as well as sociocultural (gender) differences between women and men might account for this imbalance, yet their impact on PASC is unknown. AimWe assessed the impact of sex and gender on PASC in a Swiss population. MethodOur multicentre prospective cohort study included 2,856 (46% women, mean age 44.2 ± 16.8 years) outpatients and hospitalised patients with PCR-confirmed SARS-CoV-2 infection. ResultsAmong those who remained outpatients during their first infection, women reported persisting symptoms more often than men (40.5% vs 25.5% of men; p
Læs mere
67
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19-Related Thromboembolic Events Among Medicare Enrollees Aged ≥65 Years and Those with End Stage Renal Disease - United States, September 2022-March 2023
Morbidity and Mortality Weekly Report (MMWR), 12.01.2024
Tilføjet 12.01.2024
This report describes how bivalent COVID-19 vaccines were nearly 50% effective in preventing COVID-19-related thromboembolic events among adults aged 65 and older and those on dialysis.
Læs mere
68
Spain Makes Masks Mandatory in Healthcare Centres Amid Flu, COVID Peak
Medscape Infectious Diseases, 12.01.2024
Tilføjet 12.01.2024
Spanish Health Minister Monica Garcia made wearing masks mandatory in healthcare centres around the country from Wednesday as the country faces a peak of flu and COVID-19... Reuters Health Information
Læs mere
69
Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023
Mario Fontán-Vela, Esther Kissling, Nathalie Nicolay, Toon Braeye, Izaak Van Evercooren, Christian Holm Hansen, Hanne-Dorthe Emborg, Massimo Fabiani, Alberto Mateo-Urdiales, Ala'a AlKerwi, Susanne Schmitz, Jesús Castilla, Iván Martínez-Baz, Brechje de Gier, Susan Hahné, Hinta Meijerink, Jostein Starrfelt, Baltazar Nunes, Constantino Caetano, Tarik Derrough, Anthony Nardone, Susana Monge and VEBIS-Lot4 working group
Eurosurveillance latest updates, 5.01.2024
Tilføjet 5.01.2024
To monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021–July 2023. Within 12 weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit has waned, particularly in persons ≥ 80-years-old, while some protection remained in 65–79-year-olds.
Læs mere
70
Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023
C Henri van Werkhoven, Anne-Wil Valk, Bente Smagge, Hester E de Melker, Mirjam J Knol, Susan JM Hahné, Susan van den Hof and Brechje de Gier
Eurosurveillance latest updates, 5.01.2024
Tilføjet 5.01.2024
We present early vaccine effectiveness (VE) estimates of the 2023 seasonal COVID-19 XBB.1.5 vaccine against COVID-19 hospitalisation and admission to an intensive care unit (ICU) in previously vaccinated adults ≥ 60 years in the Netherlands. We compared vaccination status of 2,050 hospitalisations including 92 ICU admissions with age group-, sex-, region- and date-specific population vaccination coverage between 9 October and 5 December 2023. VE against hospitalisation was 70.7% (95% CI: 66.6–74.3), VE against ICU admission was 73.3% (95% CI: 42.2–87.6).
Læs mere
71
Covid-19-smittebølge har toppet
Statens Serum Institut, 3.01.2024
Tilføjet 3.01.2024
De seneste ugers udbredte smitte med fem forskellige luftvejssygdomme ser nu ud til at have toppet for flere af sygdommene. Særligt covid-19, der har fyldt mest, ser ud til at være på retur, og hvis udviklingen holder stik, vil det forventeligt kunne mærkes på sygdomsbilledet de kommende uger.
Læs mere
72
Long COVID Has Caused Thousands of US Deaths: New CDC Data
Medscape Infectious Diseases, 3.01.2024
Tilføjet 3.01.2024
Fresh estimates from the CDC show a growing death tally from long COVID —– with numbers expected to increase as diagnostic expertise improves. Medscape Medical News
Læs mere
73
Long COVID: New Info on Who Is Most Likely to Get It
Medscape Infectious Diseases, 27.12.2023
Tilføjet 27.12.2023
Fresh research and clinical anecdotes have given experts a much clearer picture of which patients are most likely to develop long COVID. Medscape Medical News
Læs mere
74
CDC Says JN.1 Variant Accounts for 39%-50% Of COVID Cases in US
Medscape Infectious Diseases, 26.12.2023
Tilføjet 26.12.2023
The U.S. Centers for Disease Control and Prevention (CDC) said on Friday that COVID subvariant JN.1 accounts for 39% to 50% of cases in the United States as of Dec. 23,... Reuters Health Information
Læs mere
75
Monoclonal Antibodies: A New Treatment for Long COVID?
Medscape Infectious Diseases, 22.12.2023
Tilføjet 22.12.2023
A small study generated impressive results. Medscape Medical News
Læs mere
76
Influenza, Updated COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults - United States, Fall 2023
Morbidity and Mortality Weekly Report (MMWR), 21.12.2023
Tilføjet 21.12.2023
This report describes influenza, updated COVID-19, and respiratory syncytial virus vaccination coverage among adults.
Læs mere
77
Coverage with Influenza, Respiratory Syncytial Virus, and Updated COVID-19 Vaccines Among Nursing Home Residents - National Healthcare Safety Network, United States, December 2023
Morbidity and Mortality Weekly Report (MMWR), 21.12.2023
Tilføjet 21.12.2023
This report describes respiratory syncytial virus, influenza, and COVID-19 vaccination coverage among nursing home residents.
Læs mere
78
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022
Morbidity and Mortality Weekly Report (MMWR), 21.12.2023
Tilføjet 21.12.2023
This report describes data from two randomized, double-blind clinical trials that investigated COVID-19 rebound following treatment with or without nirmatrelvir/ritonavir.
Læs mere
79
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
Morbidity and Mortality Weekly Report (MMWR), 21.12.2023
Tilføjet 21.12.2023
CDC reviewed COVID-19 rebound studies among patients who did and did not receive antiviral treatment.
Læs mere
80
New Research Aims to Unravel Both ME/CFS and Long COVID
Medscape Infectious Diseases, 21.12.2023
Tilføjet 21.12.2023
A 2-day research conference sponsored by the US National Institutes of Health highlighted research that points to mechanisms that suggest potentially \'druggable\' pathways. Medscape Medical News
Læs mere
81
COVID Strain JN.1 Is Now a 'Variant of Interest,' WHO Says
Medscape Infectious Diseases, 21.12.2023
Tilføjet 21.12.2023
JN.1 was previously grouped with its relative, BA.2.86, but has increased so much in the past 4 weeks that the WHO moved it to standalone status. WebMD Health News
Læs mere
82
COVID Strain JN.1 Is Now a 'Variant of Interest,' WHO Says
Medscape Infectious Diseases, 21.12.2023
Tilføjet 21.12.2023
JN.1 was previously grouped with its relative, BA.2.86, but has increased so much in the past 4 weeks that the WHO moved it to standalone status. Medscape Medical News
Læs mere
83
Long-COVID Risks Vary Widely by State, Region: New Study
Medscape Infectious Diseases, 19.12.2023
Tilføjet 19.12.2023
The analysis in PLOS ONE also found that people struggling with long COVID are more likely to report mental health or mobility problems, according to the analysis. Medscape Medical News
Læs mere
84
Impact of the COVID-19 pandemic on prevalence of highly resistant microorganisms in hospitalised patients in the Netherlands, March 2020 to August 2022
Wieke Altorf-van der Kuil, Cornelia CH Wielders, Romy D Zwittink, Sabine C de Greeff, Dave A. Dongelmans, Ed J Kuijper, Daan W Notermans, Annelot F Schoffelen and on behalf of the study collaborators ISIS-AR study group
Eurosurveillance latest updates, 15.12.2023
Tilføjet 15.12.2023
BackgroundThe COVID-19 pandemic resulted in adaptation in infection control measures, increased patient transfer, high occupancy of intensive cares, downscaling of non-urgent medical procedures and decreased travelling. AimTo gain insight in the influence of these changes on antimicrobial resistance (AMR) prevalence in the Netherlands, a country with a low AMR prevalence, we estimated changes in demographics and prevalence of six highly resistant microorganisms (HRMO) in hospitalised patients in the Netherlands during COVID-19 waves (March–June 2020, October 2020–June 2021, October 2021–May 2022 and June–August 2022) and interwaves (July–September 2020 and July–September 2021) compared with pre-COVID-19 (March 2019–February 2020). MethodsWe investigated data on routine bacteriology cultures of hospitalised patients, obtained from 37 clinical microbiological laboratories participating in the national AMR surveillance. Demographic characteristics and HRMO prevalence were calculated as proportions and rates per 10,000 hospital admissions. ResultsAlthough no significant persistent changes in HRMO prevalence were detected, some relevant non-significant patterns were recognised in intensive care units. Compared with pre-COVID-19 we found a tendency towards higher prevalence of meticillin-resistant Staphylococcus aureus during waves and lower prevalence of multidrug-resistant Pseudomonas aeruginosa during interwaves. Additionally, during the first three waves, we observed significantly higher proportions and rates of cultures with Enterococcus faecium (pooled 10% vs 6% and 240 vs 120 per 10,000 admissions) and coagulase-negative Staphylococci (pooled 21% vs 14% and 500 vs 252 per 10,000 admissions) compared with pre-COVID-19. ConclusionWe observed no substantial changes in HRMO prevalence in hospitalised patients during the COVID-19 pandemic.
Læs mere
85
Notes from the Field: COVID-19 Pandemic-Related Changes in Blood Lead Screening - Chicago, Illinois, 2017-2022
Morbidity and Mortality Weekly Report (MMWR), 14.12.2023
Tilføjet 14.12.2023
This report describes decreases in blood lead level testing among young children during the COVID-19 pandemic.
Læs mere
86
Reporting Protocol for integrated respiratory virus surveillance, version 1.4
ECDC
ECDC COVID-19 updates, 13.12.2023
Tilføjet 13.12.2023
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
Læs mere
87
Federal Program Offers Free COVID, Flu At-Home Tests, Rx
Medscape Infectious Diseases, 9.12.2023
Tilføjet 9.12.2023
The Home Test to Treat program is virtual and offers at-home rapid tests, telehealth sessions, and at-home treatments to people nationwide. WebMD Health News
Læs mere
88
Wide Regional Variation in Diagnosis of Long COVID
Medscape Infectious Diseases, 8.12.2023
Tilføjet 8.12.2023
The percentage of patients with a U09.9 diagnostic code in the year after a SARS-CoV-2 infection ranged from less than 4% in one region to more than 24% in another Medscape Medical News
Læs mere
89
Anxiety, Depression Soared in Young Adults During Pandemic
Medscape Infectious Diseases, 8.12.2023
Tilføjet 8.12.2023
More than a third of young adults living in the US during the COVID-19 pandemic experienced anxiety and/or depression, an outcome that may be related to economic or social uncertainty. Medscape Medical News
Læs mere
90
Factors associated with parental intention to vaccinate their child against influenza, Finland, February to March, 2022: a web-based survey
Idil Hussein, Simopekka Vänskä, Jonas Sivelä, Tuija Leino and Hanna Nohynek
Eurosurveillance latest updates, 8.12.2023
Tilføjet 8.12.2023
BackgroundInfluenza vaccination for children aged 6 months to 6 years is included in the national vaccination programme in Finland. Although all vaccines in the programme are free of charge, national coverage of influenza vaccination among children under 3 years and 3–6 years during 2020/21 was 43% and 35% respectively, with regional differences. AimTo assess factors underlying parental vaccination intention in order to increase influenza vaccine uptake among children. MethodsWe conducted a web-based survey among parents (n = 17,844) of randomly selected eligible children (aged 6 months–6 years) in February–March 2022 in five Finnish municipalities from regions of high and low coverage. Logistic regressions were used to determine associations between vaccination intention and e.g. sociodemographic factors, attitudes and knowledge. Linkage to the national vaccination register was used to confirm realisation of vaccination intention after the study. ResultsParticipation rate was 13% (n = 2,322 parents). Influenza knowledge, trust in official information, responding parent’s education level, adherence to the vaccination programme, number of children and changes in attitudes towards vaccination since COVID-19 were all associated with intention to vaccinate. Vaccination intention for children was 64%, and realised vaccination 51%. ConclusionDespite the low participation rate, both vaccinated and unvaccinated children were represented. Influenza vaccine uptake is not dependent on a single factor. Our results identified the need for open dialogue between parents and healthcare professionals, as the lack of vaccine being offered by healthcare professionals was the most reported reason for not vaccinating.
Læs mere
91
New COVID Variant JN.1 Could Disrupt Holiday Plans
Medscape Infectious Diseases, 7.12.2023
Tilføjet 7.12.2023
\'A significant wave [of JN.1] has started here and could be blunted with a high booster rate and mitigation measures.\' WebMD Health News
Læs mere
92
Some Reasons to Get Off the Fence About COVID Booster
Medscape Infectious Diseases, 7.12.2023
Tilføjet 7.12.2023
Though many people remain on the fence about getting the latest COVID vaccine booster, new research suggests a strong argument for getting the shot this winter. Medscape Medical News
Læs mere
93
Geriatricians, Look Out for Patients With Long COVID
Medscape Infectious Diseases, 6.12.2023
Tilføjet 6.12.2023
Patients residing in nursing homes may exhibit signs of long COVID that are missed. Medscape Medical News
Læs mere
94
COVID, Flu Rates Rising Nationwide, but RSV May Have Peaked
Medscape Infectious Diseases, 6.12.2023
Tilføjet 6.12.2023
COVID-19 appears to be heading for a holiday season increase across most of the United States. WebMD Health News
Læs mere
95
COVID Vaccines Lower Risk of Serious Illness in Kids
Medscape Infectious Diseases, 1.12.2023
Tilføjet 1.12.2023
Two doses of an mRNA COVID-19 vaccine reduced hospitalizations and emergency department visits by 40%. Medscape Medical News
Læs mere
96
COVID Vaccines Likely Reversed Premature Birth Trend
Medscape Infectious Diseases, 1.12.2023
Tilføjet 1.12.2023
Researchers suggest this provides further evidence of benefit of SARS-CoV-2 vaccination before or during pregnancy. Medscape Medical News
Læs mere
97
Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case–control study, United Kingdom, 2022
Anastasia Chatzilena, Catherine Hyams, Rob Challen, Robin Marlow, Jade King, David Adegbite, Jane Kinney, Madeleine Clout, Nick Maskell, Jennifer Oliver, Adam Finn, Leon Danon and on behalf of The Avon CAP Research Group
Eurosurveillance latest updates, 1.12.2023
Tilføjet 1.12.2023
BackgroundUnderstanding the relative vaccine effectiveness (rVE) of new COVID-19 vaccine formulations against SARS-CoV-2 infection is a public health priority. A precise analysis of the rVE of monovalent and bivalent boosters given during the 2022 spring-summer and autumn-winter campaigns, respectively, in a defined population remains of interest. AimWe assessed rVE against hospitalisation for the spring-summer (fourth vs third monovalent mRNA vaccine doses) and autumn-winter (fifth BA.1/ancestral bivalent vs fourth monovalent mRNA vaccine dose) boosters. MethodsWe performed a prospective single-centre test-negative design case–control study in ≥ 75-year-old people hospitalised with COVID-19 or other acute respiratory disease. We conducted regression analyses controlling for age, sex, socioeconomic status, patient comorbidities, community SARS-CoV-2 prevalence, vaccine brand and time between baseline dose and hospitalisation. ResultsWe included 682 controls and 182 cases in the spring-summer booster analysis and 572 controls and 152 cases in the autumn-winter booster analysis. A monovalent mRNA COVID-19 vaccine as fourth dose showed 46.6% rVE (95% confidence interval (CI): 13.9–67.1) vs those not fully boosted. A bivalent mRNA COVID-19 vaccine as fifth dose had 46.7% rVE (95% CI: 18.0–65.1), compared with a fourth monovalent mRNA COVID-19 vaccine dose. ConclusionsBoth fourth monovalent and fifth BA.1/ancestral mRNA bivalent COVID-19 vaccine doses demonstrated benefit as a booster in older adults. Bivalent mRNA boosters offered similar protection against hospitalisation with Omicron infection to monovalent mRNA boosters given earlier in the year. These findings support immunisation programmes in several European countries that advised the use of BA.1/ancestral bivalent booster doses.
Læs mere
98
SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and Children Aged 6 Months-4 Years - New Vaccine Surveillance Network, United States, July 2022-September 2023
Morbidity and Mortality Weekly Report (MMWR), 1.12.2023
Tilføjet 1.12.2023
This report describes the effectiveness of COVID-19 mRNA vaccines among infants and children aged 6 months-4 years.
Læs mere
99
Interim analysis of COVID-19 vaccine effectiveness against hospitalisation and death using electronic health records in six European countries
ECDC
ECDC COVID-19 updates, 30.11.2023
Tilføjet 30.11.2023
This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses, against hospitalisation due to COVID-19 and COVID-19 related deaths in resident populations ≥50 years of age, living in the community.
Læs mere
100
COVID Vax T-Cell Responses Help B-Cell–Deficient Patients
Medscape Infectious Diseases, 30.11.2023
Tilføjet 30.11.2023
The findings demonstrate how vaccine-induced T-cell responses could potentially reduce COVID-19 severity, the authors write. Medscape Medical News
Læs mere